Literature DB >> 31288921

In Reply.

Lucie Heinzerling.   

Abstract

Year:  2019        PMID： 31288921      PMCID： PMC6637658          DOI： 10.3238/arztebl.2019.0363b

Source DB:  PubMed          Journal:  Dtsch Arztebl Int        ISSN： 1866-0452            Impact factor:   5.594


× No keyword cloud information.
  4 in total

1.  Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.

Authors:  Dirk Schadendorf; F Stephen Hodi; Caroline Robert; Jeffrey S Weber; Kim Margolin; Omid Hamid; Debra Patt; Tai-Tsang Chen; David M Berman; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-02-09       Impact factor: 44.544

Review 2.  Checkpoint Inhibitors.

Authors:  Lucie Heinzerling; Enrico N de Toni; Georg Schett; Gheorghe Hundorfean; Lisa Zimmer
Journal:  Dtsch Arztebl Int       Date:  2019-02-22       Impact factor: 5.594

3.  Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.

Authors:  Dirk Schadendorf; Reinhard Dummer; Axel Hauschild; Caroline Robert; Omid Hamid; Adil Daud; Alfons van den Eertwegh; Lee Cranmer; Steven O'Day; Igor Puzanov; Jacob Schachter; Christian Blank; April Salama; Carmen Loquai; Janice M Mehnert; Darcy Hille; Scot Ebbinghaus; S Peter Kang; Wei Zhou; Antoni Ribas
Journal:  Eur J Cancer       Date:  2016-09-02       Impact factor: 9.162

4.  Therapy preferences in melanoma treatment--willingness to pay and preference of quality versus length of life of patients, physicians and healthy controls.

Authors:  Ramona Krammer; Lucie Heinzerling
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.